Thrombin-targeted liposomes establish a sustained localized anticlotting barrier against acute thrombosis

Molecular Pharmaceutics

Volumn 10, Issue 11, 2013, Pages 4168-4175

  Palekar, Rohun U ^a   Myerson, Jacob W ^a   Schlesinger, Paul H ^b   Sadler, J Evan ^c   Pan, Hua ^c   Wickline, Samuel A ^a,b,c  

^a WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

anticoagulants; drug delivery; liposomes; nanoparticles; thrombosis

Indexed keywords

ANTICOAGULANT AGENT; LIPOSOME; NANOPARTICLE; PHENYL PROLYL ALANYL ARGINYL CHLOROMETHYL KETONE; SODIUM CHLORIDE; THROMBIN; THROMBIN INHIBITOR; TRIPEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTERY OCCLUSION; ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; CAROTID ARTERY INJURY; CLINICAL FEATURE; DRUG FORMULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHOTOCHEMISTRY; PLASMA; PRIORITY JOURNAL; THROMBOSIS;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; ANTICOAGULANTS; HUMANS; LIPOSOMES; MICE; THROMBIN; THROMBOSIS; UNILAMELLAR LIPOSOMES;

EID: 84887378680     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400210q     Document Type: Article

References (34)

1. Choi, J.; Kermode, J. C. New therapeutic approaches to combat arterial thrombosis: better drugs for old targets, novel targets, and future prospects Mol. Interv. 2011, 11, 111-123
2. Franchini, M.; Mannucci, P. M. New antiplatelet agents: why they are needed Eur. J. Intern. Med. 2009, 20, 733-738
3. Siddique, A.; Butt, M.; Shantsila, E.; Lip, G. Y. H. New antiplatelet drugs: beyond aspirin and clopidogrel Int. J. Clin. Pract. 2009, 63, 776-789
4. Lee, L. V. Anticoagulants in coronary artery disease Cardiol. Clin. 2008, 26, 615-628
5. Mackman, N. Triggers, targets and treatments for thrombosis Nature 2008, 451, 914-918
6. Gross, P. L.; Weitz, J. I. New Antithrombotic Drugs Clin. Pharmacol. Ther. 2009, 86, 139-146
7. Turpie, A. Thrombosis Research: The top 4 advances in antithrombotic care in the last year Thromb. Res. 2008, 123, S2-S6
8. Myerson, J.; He, L.; Lanza, G.; Tollefsen, D.; Wickline, S. Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis J. Thrombosis Haemostasis 2011, 9, 1292-1300
9. Shrivastava, S.; Bera, T.; Singh, S. K.; Singh, G.; Ramachandrarao, P.; Dash, D. Characterization of antiplatelet properties of silver nanoparticles ACS Nano 2009, 3, 1357-1364
10. Peters, D.; Kastantin, M.; Kotamraju, V. R.; Karmali, P. P.; Gujraty, K.; Tirrell, M.; Ruoslahti, E. Targeting atherosclerosis by using modular, multifunctional micelles Proc. Natl. Acad. Sci. 2009, 106, 9815-9819
11. Singh, S. K. S.; Singh, M. K. M.; Kulkarni, P. P. P.; Sonkar, V. K. V.; Grácio, J. J. A. J.; Dash, D. D. Amine-modified graphene: thrombo-protective safer alternative to graphene oxide for biomedical applications ACS Nano 2012, 6, 2731-2740
12. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discovery 2005, 4, 145-160
13. Vemuri, S.; Rhodes, C. Preparation and characterization of liposomes as therapeutic delivery systems: a review Pharm. Acta Helv. 1995, 70, 95-111
14. Immordino, M. L.; Dosio, F.; Cattel, L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential Int. J. Nanomed. 2006, 1, 297-315
15. Tan, M. L.; Choong, P. F. M.; Dass, C. R. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery Peptides 2010, 31, 184-193
16. Kaiser, B. Pharmacology of synthetic thrombin inhibitors of the tripeptide type Cardiovasc. Drug Rev. 1992, 10, 71-87
17. Olson, F.; Hunt, C.; Szoka, F.; Vail, W.; Papahadjopoulos, D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes Biochim. Biophys. Acta (BBA): Biomembr. 1979, 557, 9-23
18. Hood, J. L.; Roman, S. S.; Wickline, S. A. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis Cancer Res. 2011, 71, 3792-3801
19. Stewart, J. C. M. Colorimetric determination of phospholipids with ammonium ferrothiocyanate Anal. Biochem. 1980, 104, 10-14
20. Vicente, C. P.; He, L.; Pavão, M. S. G.; Tollefsen, D. M. Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice Blood 2004, 104, 3965-3970
21. Stone, S. R.; Hofsteenge, J. Kinetics of the inhibition of thrombin by hirudin Biochemistry 1986, 25, 4622-4628
22. Zhou, L.; Schmaier, A. H. Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field Am. J. Clin. Pathol. 2005, 123, 172-183
23. Jarvis, G. E. Platelet aggregation: turbidimetric measurements Methods Mol. Biol. 2004, 272, 65-76
24. Carstairs, K. C. The identification of platelets and platelet antigens in histological sections J. Pathol. Bacteriol. 1965, 90, 225-231
25. Weitz, J. I. J.; Hudoba, M. M.; Massel, D. D.; Maraganore, J. J.; Hirsh, J. J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors J. Clin. Invest. 1990, 86, 385-391
26. Hogg, P. J.; Jackson, C. M. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 3619-3623
27. Lefkovits, J.; Topol, E. J. Direct thrombin inhibitors in cardiovascular medicine Circulation 1994, 90, 1522-1536
28. Lova, P.; Canobbio, I.; Guidetti, G. F.; Balduini, C.; Torti, M. Thrombin induces platelet activation in the absence of functional protease activated receptors 1 and 4 and glycoprotein Ib-IX-V Cell. Signal. 2010, 22, 1681-1687
29. De Candia, E. Mechanisms of platelet activation by thrombin: A short history Thromb. Res. 2012, 129, 7-7
30. Dubois, C.; Steiner, B.; Kieffer, N.; Reigner, S. C. M. Thrombin binding to GPIbalpha induces platelet aggregation and fibrin clot retraction supported by resting alphaIIbbeta3 interaction with polymerized fibrin Thromb. Haemost. 2003, 89, 853-865
31. Coughlin, S. R. Thrombin signalling and protease-activated receptors Nature 2000, 407, 258-264
32. Xu, W. F. W.; Andersen, H. H.; Whitmore, T. E. T.; Presnell, S. R. S.; Yee, D. P. D.; Ching, A. A.; Gilbert, T. T.; Davie, E. W. E.; Foster, D. C. D. Cloning and characterization of human protease-activated receptor 4 Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 6642-6646
33. Kahn, M. L.; Zheng, Y. W.; Huang, W.; Bigornia, V.; Zeng, D.; Moff, S.; Farese, R. V.; Tam, C.; Coughlin, S. R. A dual thrombin receptor system for platelet activation Nature 1998, 394, 690-694
34. Nakanishi-Matsui, M.; Zheng, Y. W.; Sulciner, D. J.; Weiss, E. J.; Ludeman, M. J.; Coughlin, S. R. PAR3 is a cofactor for PAR4 activation by thrombin Nature 2000, 404, 609-613